1. Canadian Cancer Society’s Steering Committee on Cancer S. Canadian Cancer Statistics 2014. Canadian Cancer Society: Toronto, ON, 2014.
2. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M . Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2014; pii: S0302–S2838.
3. Crawford ED, Moul JW . ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Oncology (Williston Park, NY) 2015; 29: 112–126.
4. Nguyen PL, Alibhai SMH, Basaria S, D'Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2014; 67: 825–836.
5. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR . Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE Registry. Eur Urol 2014; pii: S0302–S2838.